Lilly's orforglipron is the first oral GLP-1 drug that doesn't require food and water restrictions to successfully complete a phase 3 trial. Orforglipron, given to type 2 diabetes patients ...

taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company is confident in its ability to Eli Lilly and Company (NYSE: LLY) today announced ...

Patients self-administer, through injection, the Novo Nordisk and Lilly drugs, and they do this ... but it requires specific attention to food and water intake. Other companies, such as biotech ...

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic. The stock dropped as ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

Daily pill lowered blood sugar levels by an average of 1.3%, Lilly says In trial, Type 2 diabetes patients lost nearly 8% of their body weight Company confident pill could launch worldwide without ...

Lilly sues four compounders over copies of weight-loss drugs Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and ... but patients have to swallow it first thing in the morning, with water, on an empty stomach.

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...